Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US
In this study, women receiving depot medroxyprogesterone acetate had a greater relative risk of subsequent meningioma diagnosis, especially with prolonged exposures and starting the medication at older ages. The high number needed to harm suggests low clinical risk overall.
Authors
- Divya Yogi-Morren (ORCID: https://orcid.org/0000-0001-5248-9416)
- Varun R. Kshettry (ORCID: https://orcid.org/0000-0003-3217-8279)
- Pranav Kumar (ORCID: https://orcid.org/0009-0009-2986-4332)
- Pablo F. Recinos (ORCID: https://orcid.org/0000-0002-9748-2784)
- Mina Lobbous (ORCID: https://orcid.org/0000-0002-7034-2079)
- Tianqi Xiao (ORCID: https://orcid.org/0000-0002-9474-5809)
- Pranay Soni (ORCID: https://orcid.org/0000-0003-0270-6915)
Institutions
- Cleveland Clinic Lerner College of Medicine (US)
- University School (US)
- The Neurological Institute (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- JAMA Neurology
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1001/jamaneurol.2025.3011
- Citations
- 7
- Primary Topic
- Meningioma and schwannoma management
- Type
- article
- Field-Weighted Citation Impact
- 9.48